炭疽病ワクチンの世界市場レポート 2024年

炭疽病ワクチン市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR5.2％で138億米ドルに成長すると予測されています。予測期間の成長には、世界の安全保障上の課題、新たな脅威、防衛力強化を目的とした政府調達イニシアティブ、パンデミック対策強化などが寄与するとみられます。予測期間中に予測される動向には、ワクチン開発における技術的進歩、発展途上国におけるワクチンの入手しやすさの向上、次世代ワクチンへの注目の高まり、政府備蓄イニシアティブの拡大、感染症対策を目的とした共同研究の取り組みなどが含まれます。

炭疽病ワクチン市場は、感染症の流行の高まりにより大きな成長が見込まれています。様々な病原体によって引き起こされる感染症は、公衆衛生に大きな脅威をもたらし、様々な症状や時には致命的な結果をもたらします。感染症の流行増加の要因としては、人口動態の変化、都市化、環境の変化、人間の行動の変化などが挙げられます。主に炭疽菌から身を守るために開発されたKEYWORDは、現在進行中の免疫原性と適応性の調査によって、他の感染症予防の可能性が模索されています。2023年2月に外交問題評議会（Council on Foreign Relations）が強調したように、新たに発見された感染症や新興感染症のかなりの割合が人獣共通感染症を起源としており、その影響を緩和するための効果的なワクチンの必要性が強調されています。

炭疽病ワクチン市場の主要企業は、炭疽菌に暴露されるリスクのある人々のために、安全性、有効性、入手しやすさを確保するために、革新的な製品の開発とFDA承認の取得を優先しています。FDAの承認は、ワクチンが臨床試験で厳格なテストを受け、一般に使用しても安全であると判断されたことを意味し、その安全性プロファイルについて個人に保証を与えるものです。例えば、大手バイオ医薬品会社であるEmergent BioSolutions Inc.は、2023年7月にサイフェンダス（炭疽病ワクチン Adsorbed, Adjuvanted）のFDA承認を取得しました。この承認は、既存の炭疽ワクチンと比較してワクチンの安全性と免疫原性を評価した包括的な第2相および第3相臨床試験に基づいています。さらに、アジュバント技術の進歩は、反応原性の懸念に対処し、炭疽ワクチンの全体的な有効性を高めるために極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 市場促進要因・抑制要因
  • 市場促進要因
  • 市場抑制要因
• 市場規模の実績と成長, 2018-2023
• 市場規模の予測と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

• 世界の炭疽病ワクチン市場：ワクチンタイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 無細胞PAワクチン
• 弱毒生ワクチン
• 世界の炭疽病ワクチン市場：応用タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 動物用
• 人間用
• 世界の炭疽病ワクチン市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 病院
• 薬局
• その他

第7章 地域別・国別分析

• 世界の炭疽病ワクチン市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 世界の炭疽病ワクチン市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 炭疽病ワクチン市場：競合情勢
• 炭疽病ワクチン市場：企業プロファイル
  • Merck & Co. Inc.
  • GC Biopharma
  • Emergent BioSolutions Inc.
  • Indian Immunologicals Limited
  • Valneva SE

第31章 その他の大手企業と革新的企業

• PharmAthene Inc
• Porton Biopharma Limited
• Pfenex Inc.
• Choong Ang Vaccine Laboratories Co. Ltd.
• Colorado Serum Company, Inc.
• Elusys Therapeutics Inc.
• SIGA Technologies Inc.
• Inovio Pharmaceuticals
• Botswana Vaccine Institute
• JOVAC
• Prokarium
• Soligenix Inc.
• Vaxart Inc.
• DynPort Vaccine Company LLC
• VECOL S.A

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

The anthrax vaccine is a medical product aimed at conferring immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. Comprising an inactivated form of the anthrax bacterium or its components, the vaccine stimulates the body's immune response to generate antibodies against anthrax toxins. Typically administered via injections, the vaccine involves initial doses followed by booster shots to sustain immunity over time.

The primary types of anthrax vaccine include the cell-free protective antigen (PA) vaccine and the live attenuated vaccine. The cell-free protective antigen (PA) vaccine is produced in a laboratory environment without live bacteria, involving the synthesis of the anthrax bacteria's protective antigen (PA) protein. These vaccines find applications in both animal and human use and are distributed through various channels such as hospitals, pharmacies, and others.

The anthrax vaccine market research report is one of a series of new reports from The Business Research Company that provides anthrax vaccine market statistics, including anthrax vaccine industry global market size, regional shares, competitors with a anthrax vaccine market share, detailed anthrax vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the anthrax vaccine industry. This anthrax vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthrax vaccine market size has grown steadily in recent years. It will grow from $10.74 billion in 2023 to $11.27 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be attributed to various factors, including concerns related to biological warfare, the demand from military sectors, occurrences of anthrax outbreaks, initiatives for public health preparedness, and the development of biodefense programs.

The anthrax vaccine market size is expected to see strong growth in the next few years. It will grow to $13.80 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The forecast period's growth is expected to be fueled by global security challenges, emerging threats, government procurement initiatives aimed at bolstering defense capabilities, and enhanced pandemic preparedness efforts. Anticipated trends in the forecast period encompass technological advancements in vaccine development, increased accessibility of vaccines in developing countries, a heightened focus on next-generation vaccines, expanded government stockpiling initiatives, and collaborative research efforts aimed at combating infectious diseases.

The anthrax vaccine market is expected to experience significant growth due to the rising prevalence of infectious diseases. Infectious diseases, caused by various pathogens, pose a significant threat to public health, leading to a range of symptoms and sometimes fatal outcomes. Factors contributing to the increased prevalence of infectious diseases include demographic shifts, urbanization, environmental changes, and alterations in human behavior. The anthrax vaccine, primarily designed to protect against anthrax, is being explored for its potential to prevent other infectious diseases, driven by ongoing research into its immunogenic properties and adaptability. As highlighted by the Council on Foreign Relations in February 2023, a considerable percentage of newly discovered or emerging infectious diseases have zoonotic origins, underscoring the need for effective vaccines to mitigate their impact.

Major companies in the anthrax vaccine market are prioritizing the development of innovative products and obtaining FDA approvals to ensure safety, efficacy, and accessibility for individuals at risk of anthrax exposure. FDA approval signifies that a vaccine has undergone rigorous testing in clinical trials and has been deemed safe for public use, providing assurance to individuals regarding its safety profile. For example, Emergent BioSolutions Inc., a leading biopharmaceutical company, received FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) in July 2023. This approval was based on comprehensive Phase 2 and Phase 3 clinical trials evaluating the vaccine's safety and immunogenicity compared to existing anthrax vaccines. Additionally, advancements in adjuvant technology are crucial for addressing reactogenicity concerns and enhancing the overall effectiveness of anthrax vaccines.

In October 2022, the Biomedical Advanced Research and Development Authority (BARDA) partnered with ICON plc and Rho Federal Systems Division Inc. to conduct a clinical trial evaluating the anthrax vaccine AV7909. This trial aims to assess the immunogenicity kinetics of AV7909, which combines the FDA-licensed anthrax vaccine BioThrax with an immune system stimulant. ICON plc, an Ireland-based clinical research organization, and Rho Federal Systems Division Inc., a US-based company specializing in research and development services, are collaborating with BARDA to advance anthrax vaccine research and development.

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc, Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A.

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anthrax vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anthrax vaccine market consists of sales of avirulent, nonencapsulated bacillus anthracis microaerophilic cultures, aluminum, benzethonium chloride, and formaldehyde. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anthrax Vaccine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anthrax vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anthrax vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anthrax vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine; Live Attenuated Vaccine
• 2) By Application Type: Animal Use; Human Use
• 3) By Distribution Channel: Hospitals; Pharmacies; Other Distribution Channels
• Companies Mentioned: Merck & Co. Inc.; GC Biopharma; Emergent BioSolutions Inc.; Indian Immunologicals Limited; Valneva SE
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anthrax Vaccine Market Characteristics

3. Anthrax Vaccine Market Trends And Strategies

4. Anthrax Vaccine Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Anthrax Vaccine Market Size and Growth

• 5.1. Global Anthrax Vaccine Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Anthrax Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Anthrax Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anthrax Vaccine Market Segmentation

• 6.1. Global Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cell-Free Protective Antigen (PA) Vaccine
• Live Attenuated Vaccine
• 6.2. Global Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Animal Use
• Human Use
• 6.3. Global Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Pharmacies
• Other Distribution Channels

7. Anthrax Vaccine Market Regional And Country Analysis

• 7.1. Global Anthrax Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Anthrax Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anthrax Vaccine Market

• 8.1. Asia-Pacific Anthrax Vaccine Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anthrax Vaccine Market

• 9.1. China Anthrax Vaccine Market Overview
• 9.2. China Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anthrax Vaccine Market

• 10.1. India Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anthrax Vaccine Market

• 11.1. Japan Anthrax Vaccine Market Overview
• 11.2. Japan Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anthrax Vaccine Market

• 12.1. Australia Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anthrax Vaccine Market

• 13.1. Indonesia Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anthrax Vaccine Market

• 14.1. South Korea Anthrax Vaccine Market Overview
• 14.2. South Korea Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anthrax Vaccine Market

• 15.1. Western Europe Anthrax Vaccine Market Overview
• 15.2. Western Europe Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anthrax Vaccine Market

• 16.1. UK Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anthrax Vaccine Market

• 17.1. Germany Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anthrax Vaccine Market

• 18.1. France Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anthrax Vaccine Market

• 19.1. Italy Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anthrax Vaccine Market

• 20.1. Spain Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anthrax Vaccine Market

• 21.1. Eastern Europe Anthrax Vaccine Market Overview
• 21.2. Eastern Europe Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anthrax Vaccine Market

• 22.1. Russia Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anthrax Vaccine Market

• 23.1. North America Anthrax Vaccine Market Overview
• 23.2. North America Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anthrax Vaccine Market

• 24.1. USA Anthrax Vaccine Market Overview
• 24.2. USA Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anthrax Vaccine Market

• 25.1. Canada Anthrax Vaccine Market Overview
• 25.2. Canada Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anthrax Vaccine Market

• 26.1. South America Anthrax Vaccine Market Overview
• 26.2. South America Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anthrax Vaccine Market

• 27.1. Brazil Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anthrax Vaccine Market

• 28.1. Middle East Anthrax Vaccine Market Overview
• 28.2. Middle East Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anthrax Vaccine Market

• 29.1. Africa Anthrax Vaccine Market Overview
• 29.2. Africa Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anthrax Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Anthrax Vaccine Market Competitive Landscape
• 30.2. Anthrax Vaccine Market Company Profiles
  • 30.2.1. Merck & Co. Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. GC Biopharma
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Emergent BioSolutions Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Indian Immunologicals Limited
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Valneva SE
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Anthrax Vaccine Market Other Major And Innovative Companies

• 31.1. PharmAthene Inc
• 31.2. Porton Biopharma Limited
• 31.3. Pfenex Inc.
• 31.4. Choong Ang Vaccine Laboratories Co. Ltd.
• 31.5. Colorado Serum Company, Inc.
• 31.6. Elusys Therapeutics Inc.
• 31.7. SIGA Technologies Inc.
• 31.8. Inovio Pharmaceuticals
• 31.9. Botswana Vaccine Institute
• 31.10. JOVAC
• 31.11. Prokarium
• 31.12. Soligenix Inc.
• 31.13. Vaxart Inc.
• 31.14. DynPort Vaccine Company LLC
• 31.15. VECOL S.A

32. Global Anthrax Vaccine Market Competitive Benchmarking

33. Global Anthrax Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Anthrax Vaccine Market

35. Anthrax Vaccine Market Future Outlook and Potential Analysis

• 35.1 Anthrax Vaccine Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Anthrax Vaccine Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Anthrax Vaccine Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer